Please assess the completion status of the following clinical trial:

Trial Title: Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years, male or female~* Signed written informed consent~* Patients with histologically confirmed diagnosis of colorectal cancer with hepatic metastases who are candidates for systemic treatment.~* Confirmation of metastatic liver disease within one month prior to inclusion in one of the following radiological procedures:~  * Contrast-enhanced spiral computed tomography showing at least one liver nodule ≥ 20 mm in longest diameter according to RECIST 1.1 criteria~ * MR imaging of the liver with liver lesions suspicious for metastases~ * PET computed tomography (PET/CT) with liver lesions suspicious for metastases~* Patient is eligible and designated for treatment with standard-of-care first-line bevacizumab-containing, fluoropyrimidine-based chemotherapy.~* ECOG performance status ≤ 2 (see appendix)~Exclusion Criteria:~* Inability or unwillingness to comply with the participation requirements~* History of untreated hyperthyreosis~* History of intolerance of or allergy to iodine contrast media according to CTCAE V4.03~* Calculated creatinine clearance \< 45 ml/min~* For fertile women: positive urine pregnancy test or lactation.~* Known or suspected non-compliance, drug or alcohol abuse~* Life expectancy of less than 3 months~* Participation in another interventional trial with an investigational medicinal product (IMP) and within 30 days prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Perfusion-computed tomography (CTP) (Type: OTHER): Patients undergo a total of four perfusion-computed tomographies from baseline to progression of disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).